Determining the Potency and Molecular Mechanism of Action of Insurmountable Antagonists
Open Access
- 1 November 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 319 (2) , 710-723
- https://doi.org/10.1124/jpet.106.107375
Abstract
Insurmountable antagonism (maximal response to the agonist depressed) can result from a temporal inequilibrium involving a slow offset orthosteric antagonist or be the result of an allosteric modulation of the receptor. The former mechanism is operative when the antagonist, agonist, and receptors cannot come to proper equilibrium during the time allotted for collection of agonist response (hemi-equilibrium conditions). Allosteric effects (changes in the conformation of the receptor through binding of the allosteric modulator to a separate site) can preclude the agonist-induced production of response, leading to depression of maximal responses. In these cases, the effects on receptor affinity can be observed as well. The first premise of this article is that system-independent estimates of insurmountable antagonist potency can be made with no prior knowledge of molecular mechanism through the use of pA2 (–log molar concentration of antagonist producing a 2-fold shift of the concentration response curve) measurements The relationship between the pA2 and antagonist pKB (–log equilibrium dissociation constant of the antagonist-receptor complex) is described; the former is an extremely close approximation of the latter in most cases. The second premise is that specially designed experiments are required to differentiate orthosteric versus allosteric mechanisms; simply fitting of data to orthosteric or allosteric theoretical models can lead to ambiguous results. A strategy to determine whether the observed antagonism is orthosteric (agonist and antagonist competing for the same binding site on the receptor) or allosteric in nature is described that involves the detection of the hallmarks of allosteric response, namely saturation and probe dependence of effect.This publication has 30 references indexed in Scilit:
- New Concepts in Drug Discovery: Collateral Efficacy and Permissive AntagonismNature Reviews Drug Discovery, 2005
- The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry InhibitorMolecular Pharmacology, 2005
- Allosteric Modulators: The New Generation of Receptor AntagonistMolecular Interventions, 2004
- Identification of Allosteric Peptide Agonists of CXCR4Journal of Biological Chemistry, 2003
- Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscleBritish Journal of Pharmacology, 2001
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998
- The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tractNature, 1998
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1Nature, 1996
- The mechanism of action of 2-halogenoethylamines at the adrenergic α-receptor and a further investigation of the “spare receptor” hypothesisJournal of Pharmacy and Pharmacology, 1969
- The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptorsProceedings of the Royal Society of London. B. Biological Sciences, 1965